Cosmos Health targets 2029 revenue of $200.6 million, gross profit of $71.2 million

• Cosmos Health reiterated 2029 targets of USD 200.6 million revenue, USD 71.2 million gross profit, citing contract manufacturing as a key driver.
• Contract manufacturing pipeline at Cana Laboratories exceeded USD 20 million implied revenue, implying over USD 18 million gross profit at over 90% margins.
• Management estimates the current pipeline equates to about USD 5 million implied annual revenue, about USD 4.5 million implied annual gross profit.
• Production pipeline reached 32,700,000 units, up about sixfold since mid-2024, supporting a goal of over USD 10 million recurring annual gross profit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.